JP4057049B2 - 置換クロマトグラフィー法および精製ヘモグロビン産物 - Google Patents

置換クロマトグラフィー法および精製ヘモグロビン産物 Download PDF

Info

Publication number: JP4057049B2
Authority: JP; Japan
Prior art keywords: column; hemoglobin; stage; chromatography; hbao
Prior art date: 1993-09-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

JP50945895A

Other languages

English (en)

Japanese (ja)

Other versions

JPH08503714A (ja

Inventor

プリウラ、ダイアナ

ワイフェン、ダイアン

アシュラフ、サルマン

マグニン、アンソニー・エー

Original Assignee

ヘモソルインコーポレーテッド

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-09-21

Filing date

1994-09-20

Publication date

2008-03-05

1993-09-21 Priority claimed from CA002106612A external-priority patent/CA2106612C/en

1994-09-20 Application filed by ヘモソルインコーポレーテッド filed Critical ヘモソルインコーポレーテッド

1996-04-23 Publication of JPH08503714A publication Critical patent/JPH08503714A/ja

2008-03-05 Application granted granted Critical

2008-03-05 Publication of JP4057049B2 publication Critical patent/JP4057049B2/ja

2023-03-05 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

108010054147 Hemoglobins Proteins 0.000 title claims abstract description 181
102000001554 Hemoglobins Human genes 0.000 title claims abstract description 181
238000002086 displacement chromatography Methods 0.000 title description 10
238000000034 method Methods 0.000 claims abstract description 99
230000002378 acidificating effect Effects 0.000 claims abstract description 20
238000004587 chromatography analysis Methods 0.000 claims description 33
238000005349 anion exchange Methods 0.000 claims description 20
239000012527 feed solution Substances 0.000 claims description 15
238000005341 cation exchange Methods 0.000 claims description 14
210000003743 erythrocyte Anatomy 0.000 claims description 13
238000005277 cation exchange chromatography Methods 0.000 claims description 11
230000008569 process Effects 0.000 claims description 11
238000005342 ion exchange Methods 0.000 claims description 9
239000012045 crude solution Substances 0.000 claims description 7
238000006073 displacement reaction Methods 0.000 claims description 5
150000001768 cations Chemical class 0.000 claims 1
238000011210 chromatographic step Methods 0.000 claims 1
230000001747 exhibiting effect Effects 0.000 claims 1
238000004255 ion exchange chromatography Methods 0.000 abstract description 7
238000006467 substitution reaction Methods 0.000 abstract description 5
238000011097 chromatography purification Methods 0.000 abstract description 3
239000000047 product Substances 0.000 description 49
239000000243 solution Substances 0.000 description 49
239000000356 contaminant Substances 0.000 description 43
102000004169 proteins and genes Human genes 0.000 description 42
108090000623 proteins and genes Proteins 0.000 description 42
241000894007 species Species 0.000 description 27
241000700605 Viruses Species 0.000 description 21
238000001155 isoelectric focusing Methods 0.000 description 21
108010001708 stroma free hemoglobin Proteins 0.000 description 21
238000011068 loading method Methods 0.000 description 20
238000000746 purification Methods 0.000 description 20
239000003656 tris buffered saline Substances 0.000 description 19
102000008100 Human Serum Albumin Human genes 0.000 description 18
108091006905 Human Serum Albumin Proteins 0.000 description 18
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
239000003633 blood substitute Substances 0.000 description 17
239000000872 buffer Substances 0.000 description 16
238000011534 incubation Methods 0.000 description 16
239000006166 lysate Substances 0.000 description 16
102000004506 Blood Proteins Human genes 0.000 description 15
108010017384 Blood Proteins Proteins 0.000 description 15
210000004369 blood Anatomy 0.000 description 14
239000008280 blood Substances 0.000 description 14
210000004027 cell Anatomy 0.000 description 14
239000000499 gel Substances 0.000 description 14
239000000203 mixture Substances 0.000 description 14
102000003855 L-lactate dehydrogenase Human genes 0.000 description 13
108700023483 L-lactate dehydrogenases Proteins 0.000 description 13
239000007983 Tris buffer Substances 0.000 description 13
210000002889 endothelial cell Anatomy 0.000 description 13
239000012535 impurity Substances 0.000 description 13
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 13
238000004458 analytical method Methods 0.000 description 12
238000005571 anion exchange chromatography Methods 0.000 description 12
238000003556 assay Methods 0.000 description 12
230000000694 effects Effects 0.000 description 11
108010010803 Gelatin Proteins 0.000 description 10
241000700159 Rattus Species 0.000 description 10
239000000427 antigen Substances 0.000 description 10
102000036639 antigens Human genes 0.000 description 10
108091007433 antigens Proteins 0.000 description 10
238000010828 elution Methods 0.000 description 10
239000008273 gelatin Substances 0.000 description 10
229920000159 gelatin Polymers 0.000 description 10
235000019322 gelatine Nutrition 0.000 description 10
235000011852 gelatine desserts Nutrition 0.000 description 10
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
239000003957 anion exchange resin Substances 0.000 description 9
239000002609 medium Substances 0.000 description 9
238000011084 recovery Methods 0.000 description 9
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 8
230000004872 arterial blood pressure Effects 0.000 description 8
238000002474 experimental method Methods 0.000 description 8
239000002245 particle Substances 0.000 description 8
239000011780 sodium chloride Substances 0.000 description 8
241000283690 Bos taurus Species 0.000 description 7
239000012085 test solution Substances 0.000 description 7
241000251468 Actinopterygii Species 0.000 description 6
230000008901 benefit Effects 0.000 description 6
-1 equipment Substances 0.000 description 6
238000002347 injection Methods 0.000 description 6
239000007924 injection Substances 0.000 description 6
238000002360 preparation method Methods 0.000 description 6
210000002966 serum Anatomy 0.000 description 6
230000005526 G1 to G0 transition Effects 0.000 description 5
241000725303 Human immunodeficiency virus Species 0.000 description 5
230000005779 cell damage Effects 0.000 description 5
238000001802 infusion Methods 0.000 description 5
239000007788 liquid Substances 0.000 description 5
239000003550 marker Substances 0.000 description 5
150000003904 phospholipids Chemical class 0.000 description 5
238000000926 separation method Methods 0.000 description 5
238000012360 testing method Methods 0.000 description 5
231100000419 toxicity Toxicity 0.000 description 5
230000001988 toxicity Effects 0.000 description 5
JWICNZAGYSIBAR-LEEGLKINSA-N (4s)-4-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-2-aminopropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-5-[[2-[[(2s)-3-carboxy-1-[[(2s)-1-[[1-[[(2s)-1-[[(2s)-4-carboxy-1-[[2-[[2-[[2-[[(2s)-1-[[(1s)-1-carboxy-4-(diaminomethylideneamino Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)C(CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)N)CC1=CC=CC=C1 JWICNZAGYSIBAR-LEEGLKINSA-N 0.000 description 4
229920000936 Agarose Polymers 0.000 description 4
206010012735 Diarrhoea Diseases 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
101800000974 Fibrinopeptide A Proteins 0.000 description 4
102400000525 Fibrinopeptide A Human genes 0.000 description 4
239000000020 Nitrocellulose Substances 0.000 description 4
241000283973 Oryctolagus cuniculus Species 0.000 description 4
239000007864 aqueous solution Substances 0.000 description 4
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
230000023555 blood coagulation Effects 0.000 description 4
230000036772 blood pressure Effects 0.000 description 4
208000037887 cell injury Diseases 0.000 description 4
125000003636 chemical group Chemical group 0.000 description 4
238000010586 diagram Methods 0.000 description 4
238000001914 filtration Methods 0.000 description 4
239000012528 membrane Substances 0.000 description 4
229920001220 nitrocellulos Polymers 0.000 description 4
239000001301 oxygen Substances 0.000 description 4
229910052760 oxygen Inorganic materials 0.000 description 4
239000000126 substance Substances 0.000 description 4
230000003612 virological effect Effects 0.000 description 4
208000032456 Hemorrhagic Shock Diseases 0.000 description 3
108010052285 Membrane Proteins Proteins 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
108010064719 Oxyhemoglobins Proteins 0.000 description 3
206010049771 Shock haemorrhagic Diseases 0.000 description 3
241000700584 Simplexvirus Species 0.000 description 3
206010047139 Vasoconstriction Diseases 0.000 description 3
150000001450 anions Chemical class 0.000 description 3
239000003729 cation exchange resin Substances 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
230000003013 cytotoxicity Effects 0.000 description 3
231100000135 cytotoxicity Toxicity 0.000 description 3
238000011161 development Methods 0.000 description 3
230000018109 developmental process Effects 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
210000000265 leukocyte Anatomy 0.000 description 3
239000012160 loading buffer Substances 0.000 description 3
239000000463 material Substances 0.000 description 3
239000011159 matrix material Substances 0.000 description 3
238000012544 monitoring process Methods 0.000 description 3
239000002244 precipitate Substances 0.000 description 3
230000002947 procoagulating effect Effects 0.000 description 3
239000011347 resin Substances 0.000 description 3
229920005989 resin Polymers 0.000 description 3
239000007790 solid phase Substances 0.000 description 3
238000010561 standard procedure Methods 0.000 description 3
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 3
230000025033 vasoconstriction Effects 0.000 description 3
KDMJJWMGEVWNLB-OSLXHZNNSA-N (2s)-3-hydroxy-2-[(2r)-1-hydroxy-3-oxopropan-2-yl]oxy-2-[(1r)-1-[(2r)-1-[(1s)-1-[(2r)-1-hydroxy-3-oxopropan-2-yl]oxy-2-oxoethoxy]-3-oxopropan-2-yl]oxy-2-oxoethoxy]propanal Chemical compound OC[C@H](C=O)O[C@@H](C=O)OC[C@H](C=O)O[C@@H](C=O)O[C@@](CO)(C=O)O[C@H](CO)C=O KDMJJWMGEVWNLB-OSLXHZNNSA-N 0.000 description 2
MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 2
102000009027 Albumins Human genes 0.000 description 2
108010088751 Albumins Proteins 0.000 description 2
238000002965 ELISA Methods 0.000 description 2
241000991587 Enterovirus C Species 0.000 description 2
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
108010001336 Horseradish Peroxidase Proteins 0.000 description 2
241000700588 Human alphaherpesvirus 1 Species 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
239000011543 agarose gel Substances 0.000 description 2
238000013459 approach Methods 0.000 description 2
OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 2
239000006143 cell culture medium Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000013375 chromatographic separation Methods 0.000 description 2
238000011109 contamination Methods 0.000 description 2
239000003431 cross linking reagent Substances 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
238000011026 diafiltration Methods 0.000 description 2
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
238000001962 electrophoresis Methods 0.000 description 2
239000012149 elution buffer Substances 0.000 description 2
239000002158 endotoxin Substances 0.000 description 2
229960002897 heparin Drugs 0.000 description 2
229920000669 heparin Polymers 0.000 description 2
238000012744 immunostaining Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
238000011031 large-scale manufacturing process Methods 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
230000004792 oxidative damage Effects 0.000 description 2
238000009928 pasteurization Methods 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
230000036584 pressor response Effects 0.000 description 2
239000002510 pyrogen Substances 0.000 description 2
238000011069 regeneration method Methods 0.000 description 2
230000004044 response Effects 0.000 description 2
238000003118 sandwich ELISA Methods 0.000 description 2
238000001179 sorption measurement Methods 0.000 description 2
238000010186 staining Methods 0.000 description 2
238000012289 standard assay Methods 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
230000003639 vasoconstrictive effect Effects 0.000 description 2
210000003462 vein Anatomy 0.000 description 2
238000005406 washing Methods 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
238000001262 western blot Methods 0.000 description 2
DSLBDPPHINVUID-REOHCLBHSA-N (2s)-2-aminobutanediamide Chemical compound NC(=O)[C@@H](N)CC(N)=O DSLBDPPHINVUID-REOHCLBHSA-N 0.000 description 1
INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical compound N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 description 1
WXHLLJAMBQLULT-UHFFFAOYSA-N 2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-n-(2-methyl-6-sulfanylphenyl)-1,3-thiazole-5-carboxamide;hydrate Chemical compound O.C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1S WXHLLJAMBQLULT-UHFFFAOYSA-N 0.000 description 1
125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
LVSPDZAGCBEQAV-UHFFFAOYSA-N 4-chloronaphthalen-1-ol Chemical compound C1=CC=C2C(O)=CC=C(Cl)C2=C1 LVSPDZAGCBEQAV-UHFFFAOYSA-N 0.000 description 1
102000002572 Alpha-Globulins Human genes 0.000 description 1
108010068307 Alpha-Globulins Proteins 0.000 description 1
102000006734 Beta-Globulins Human genes 0.000 description 1
108010087504 Beta-Globulins Proteins 0.000 description 1
244000025254 Cannabis sativa Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
238000011537 Coomassie blue staining Methods 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
108010074860 Factor Xa Proteins 0.000 description 1
108010044495 Fetal Hemoglobin Proteins 0.000 description 1
108010049003 Fibrinogen Proteins 0.000 description 1
102000008946 Fibrinogen Human genes 0.000 description 1
239000004606 Fillers/Extenders Substances 0.000 description 1
102000006395 Globulins Human genes 0.000 description 1
108010044091 Globulins Proteins 0.000 description 1
206010018910 Haemolysis Diseases 0.000 description 1
208000005176 Hepatitis C Diseases 0.000 description 1
241000709701 Human poliovirus 1 Species 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
239000008118 PEG 6000 Substances 0.000 description 1
229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
239000012518 Poros HS 50 resin Substances 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
241000473945 Theria <moth genus> Species 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000009471 action Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
150000001412 amines Chemical group 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
210000002376 aorta thoracic Anatomy 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
239000002473 artificial blood Substances 0.000 description 1
JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 description 1
238000010923 batch production Methods 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
230000037396 body weight Effects 0.000 description 1
238000009835 boiling Methods 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229910002091 carbon monoxide Inorganic materials 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
150000007942 carboxylates Chemical class 0.000 description 1
125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
210000001715 carotid artery Anatomy 0.000 description 1
239000000969 carrier Substances 0.000 description 1
229940023913 cation exchange resins Drugs 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
239000000919 ceramic Substances 0.000 description 1
230000008859 change Effects 0.000 description 1
229920001429 chelating resin Polymers 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
238000007813 chromatographic assay Methods 0.000 description 1
239000012504 chromatography matrix Substances 0.000 description 1
239000012501 chromatography medium Substances 0.000 description 1
238000011035 continuous diafiltration Methods 0.000 description 1
238000010924 continuous production Methods 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
238000007821 culture assay Methods 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000011118 depth filtration Methods 0.000 description 1
238000011033 desalting Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
238000007786 electrostatic charging Methods 0.000 description 1
239000003480 eluent Substances 0.000 description 1
210000003038 endothelium Anatomy 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
238000011067 equilibration Methods 0.000 description 1
210000003617 erythrocyte membrane Anatomy 0.000 description 1
238000002146 exchange transfusion Methods 0.000 description 1
229940012952 fibrinogen Drugs 0.000 description 1
239000012530 fluid Substances 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000011521 glass Substances 0.000 description 1
150000003278 haem Chemical class 0.000 description 1
238000005534 hematocrit Methods 0.000 description 1
230000000004 hemodynamic effect Effects 0.000 description 1
108010036302 hemoglobin AS Proteins 0.000 description 1
230000008588 hemolysis Effects 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
239000012510 hollow fiber Substances 0.000 description 1
230000001631 hypertensive effect Effects 0.000 description 1
210000003090 iliac artery Anatomy 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
238000003119 immunoblot Methods 0.000 description 1
230000006872 improvement Effects 0.000 description 1
230000006698 induction Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
239000012500 ion exchange media Substances 0.000 description 1
238000002843 lactate dehydrogenase assay Methods 0.000 description 1
239000003446 ligand Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
230000002934 lysing effect Effects 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
239000002923 metal particle Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
239000013642 negative control Substances 0.000 description 1
VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
238000010979 pH adjustment Methods 0.000 description 1
102000013415 peroxidase activity proteins Human genes 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
239000012071 phase Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
238000011020 pilot scale process Methods 0.000 description 1
229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
229920000193 polymethacrylate Polymers 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
229920005553 polystyrene-acrylate Polymers 0.000 description 1
238000003825 pressing Methods 0.000 description 1
238000011106 process-scale chromatography Methods 0.000 description 1
238000011002 quantification Methods 0.000 description 1
238000011552 rat model Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000013341 scale-up Methods 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
230000035939 shock Effects 0.000 description 1
229920000260 silastic Polymers 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
238000010572 single replacement reaction Methods 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
125000001174 sulfone group Chemical group 0.000 description 1
239000010414 supernatant solution Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000003104 tissue culture media Substances 0.000 description 1
238000000825 ultraviolet detection Methods 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
239000005526 vasoconstrictor agent Substances 0.000 description 1
229940124549 vasodilator Drugs 0.000 description 1
239000003071 vasodilator agent Substances 0.000 description 1
239000011534 wash buffer Substances 0.000 description 1
239000002699 waste material Substances 0.000 description 1

Images

Classifications

- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
- B01D15/422—Displacement mode
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/795—Porphyrin- or corrin-ring-containing peptides
- C07K14/805—Haemoglobins; Myoglobins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Chemical Kinetics & Catalysis (AREA)
Genetics & Genomics (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Analytical Chemistry (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Investigating Or Analysing Biological Materials (AREA)

JP50945895A 1993-09-21 1994-09-20 置換クロマトグラフィー法および精製ヘモグロビン産物 Expired - Fee Related JP4057049B2 (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
CA002106612A CA2106612C (en)	1993-09-21	1993-09-21	Displacement chromatography process
CA2,106,612		1993-09-21
PCT/CA1994/000514 WO1995008574A1 (en)	1993-09-21	1994-09-20	Displacement chromatography process and purified hemoglobin product

Publications (2)

Publication Number	Publication Date
JPH08503714A JPH08503714A (ja)	1996-04-23
JP4057049B2 true JP4057049B2 (ja)	2008-03-05

Family

ID=4152343

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP50945895A Expired - Fee Related JP4057049B2 (ja)	1993-09-21	1994-09-20	置換クロマトグラフィー法および精製ヘモグロビン産物

Country Status (9)

Country	Link
JP (1)	JP4057049B2 (de)
KR (1)	KR100361894B1 (de)
AT (1)	ATE175975T1 (de)
DE (1)	DE69416103T2 (de)
DK (1)	DK0668877T3 (de)
ES (1)	ES2126775T3 (de)
HU (1)	HU218159B (de)
RU (1)	RU2145873C1 (de)
UA (1)	UA35599C2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8153009B2 (en) *	2005-04-22	2012-04-10	Waters Technologies Corporation	Apparatus and methods for mass-spectrometric directed purification of biopolymers
RU2329826C1 (ru) *	2006-12-29	2008-07-27	Институт высокомолекулярных соединений РАН (ИВС РАН)	Способ получения растворов гемоглобина, очищенных от стромальных компонентов
AU2010292897B2 (en) *	2009-08-06	2016-01-07	Genentech, Inc.	Method to improve virus removal in protein purification
AU2011329053A1 (en) *	2010-11-15	2013-06-06	Biogen Inc.	Enrichment and concentration of select product isoforms by overloaded bind and elute chromatography
US10364268B2 (en)	2011-12-22	2019-07-30	Genentech, Inc.	Ion exchange membrane chromatography
TWI631132B (zh)	2013-05-06	2018-08-01	賽諾菲公司	用於純化抗體之連續多步驟方法
EP3546475A1 (de)	2018-03-27	2019-10-02	Sanofi	Volldurchflussverfahren zur reinigung rekombinanter proteine
TW202128264A (zh) *	2019-09-25	2021-08-01	瑞士商赫孚孟拉羅股份公司	使用經預測之溶離緩衝鹽濃度的陽離子層析法
CN116802206A (zh) *	2020-12-28	2023-09-22	等离子体技术有限责任公司	用于生产规模的免疫球蛋白g分离系统和方法
CN114712894B (zh) *	2022-04-08	2024-04-30	无锡博慧斯生物医药科技有限公司	一种糖化血红蛋白层析柱的活化液、活化方法和应用

1994
- 1994-09-20 DK DK94926756T patent/DK0668877T3/da active
- 1994-09-20 HU HU9501479A patent/HU218159B/hu not_active IP Right Cessation
- 1994-09-20 RU RU95112503A patent/RU2145873C1/ru not_active IP Right Cessation
- 1994-09-20 DE DE69416103T patent/DE69416103T2/de not_active Expired - Fee Related
- 1994-09-20 AT AT94926756T patent/ATE175975T1/de not_active IP Right Cessation
- 1994-09-20 JP JP50945895A patent/JP4057049B2/ja not_active Expired - Fee Related
- 1994-09-20 UA UA95058439A patent/UA35599C2/uk unknown
- 1994-09-20 ES ES94926756T patent/ES2126775T3/es not_active Expired - Lifetime
- 1994-09-21 KR KR1019950701487A patent/KR100361894B1/ko not_active Expired - Fee Related

Also Published As

Publication number	Publication date
RU2145873C1 (ru)	2000-02-27
RU95112503A (ru)	1996-12-20
HU9501479D0 (en)	1995-07-28
ES2126775T3 (es)	1999-04-01
ATE175975T1 (de)	1999-02-15
HUT72924A (en)	1996-06-28
UA35599C2 (uk)	2001-04-16
DE69416103T2 (de)	1999-08-05
JPH08503714A (ja)	1996-04-23
KR100361894B1 (ko)	2003-05-12
HU218159B (hu)	2000-06-28
DE69416103D1 (de)	1999-03-04
DK0668877T3 (da)	1999-09-13

Legal Events

Date	Code	Title	Description
2004-05-20	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040427
2004-09-07	A02	Decision of refusal	Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20040907
2004-12-07	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041206
2004-12-24	A911	Transfer to examiner for re-examination before appeal (zenchi)	Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20041224
2005-07-13	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050712
2005-10-13	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20051012
2005-10-18	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20051017
2006-01-13	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060112
2006-02-28	A912	Re-examination (zenchi) completed and case transferred to appeal board	Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20060223
2007-10-18	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071017
2007-12-20	A61	First payment of annual fees (during grant procedure)	Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20071213
2007-12-21	R150	Certificate of patent or registration of utility model	Free format text: JAPANESE INTERMEDIATE CODE: R150
2007-12-27	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20101221 Year of fee payment: 3
2010-12-21	LAPS	Cancellation because of no payment of annual fees

Publication	Publication Date	Title
EP0668877B1 (de)	1999-01-20	Verdrängungschromatographisches verfahren und gereinigtes hämoglobin
US5169936A (en)	1992-12-08	Protein purification on immobilized metal affinity resins effected by elution using a weak ligand
Martodam et al.	1979	A rapid procedure for the large scale purification of elastase and cathepsin G from human sputum
US5545328A (en)	1996-08-13	Purification of hemoglobin by displacement chromatography
JP3094167B2 (ja)	2000-10-03	免疫血清グロブリンの精製方法
AU718557B2 (en)	2000-04-13	A method for chromatographic removal of prions
JP2562192B2 (ja)	1996-12-11	血清アルブミンの純化方法
JP4250769B2 (ja)	2009-04-08	高度に精製されたｖＷＦまたは因子ＶＩＩＩ／ｖＷＦ複合体を得る方法
US5252217A (en)	1993-10-12	Blood coagulation factor XI concentrate having high specific activity, suitable for therapeutic use, and process for preparing same
EP0469985A1 (de)	1992-02-05	Verfahren zur Herstellung des Von Willebrand-Faktors von höchster Reinheit
JPH0533239B2 (de)	1993-05-19
KR100361894B1 (ko)	2003-05-12	치환크로마토그라피방법및정제된헤모글로빈생성물
CZ281912B6 (cs)	1997-03-12	Směs hemoglobinu síťovaného imidoesterem a způso b její výroby
Warecka et al.	1972	HUMAN BRAIN‐SPECIFIC ALPHA2‐GLYCOPROTEIN: PURIFICATION BY AFFINITY CHROMATOGRAPHY AND DETECTION OF A NEW COMPONENT; LOCALIZATION IN NERVOUS CELLS 1
JPH0381290A (ja)	1991-04-05	精製されたアルブミン溶液の製造方法
JP2002540912A (ja)	2002-12-03	生物学的混入物の除去
US9145448B2 (en)	2015-09-29	Method for the isolation of haptoglobin
HAMOGLOBIN et al.	0	EUROPEAN PATENT SPECIFICATION
Paulssen et al.	1969	Purification of the antihemophilic factor by gel filtration on agarose
JPS5810522A (ja)	1983-01-21	不活化トロンビンゲルによるアンチトロンビン３の精製法
Critz et al.	1981	Affinity Chromatographic Purification of Endogenous Pyrogen with Cibacron Blue.